论文部分内容阅读
目的探讨孟鲁斯特治疗咳嗽变异性哮喘的疗效。方法咳嗽变异性哮喘患儿192例随机分为三组:Ⅰ组吸入布地奈德;Ⅱ组口服孟鲁司特;Ⅲ组口服酮替芬。结果孟钽司特组68例,治疗后显效52例,有效9例,总有效率89.7%;而地奈德组58例,治疗后显产39例,有效6例,总有效率77.6%;酮替芬组66例,治疗后显效15例,有效11例,总有效率39.4%,各组总有效率比较,差异有统计学意义。结论口服孟鲁斯特治疗儿童咳嗽变异性哮喘效果优于糖皮质激素及酮替芬,且患儿依从性好。
Objective To investigate the efficacy of Montelukast in the treatment of cough variant asthma. Methods 192 children with cough variant asthma were randomly divided into three groups: group Ⅰ inhaled budesonide; group Ⅱ oral montelukast; group Ⅲ oral ketotifen. Results In the group of Monte Tantalite 68 cases, 52 cases were effective after treatment, 9 cases were effective and the total effective rate was 89.7%; 58 cases were treated with desonid, 39 cases were significant after treatment, 6 cases were effective and the total effective rate was 77.6%. Ketotifen group 66 cases, 15 cases after treatment markedly effective in 11 cases, the total effective rate was 39.4%, the total effective rate of each group, the difference was statistically significant. Conclusion Oral Montelukast treatment of children with cough variant asthma is better than glucocorticoid and ketotifen, and children with good compliance.